Saturday 17 October 2026
Export DMAA’s income statement to Excel — free account
Drugs Made In America Acquisition Corp.
DMAA Financial Shell Companies
10.87
0.00
0.00%
Follow DMAA
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Trend | 2027e | 2028e | 2029e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | 9.95 | 10.37 |
Analyst estimates 2027–2029 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | 10.37 | 10.89 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | — | — | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | — | — | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | |||||
| EBT | — | — | — | — | — | — | — | — | — | — | |||||
| EBT margin, % | — | — | — | — | — | — | — | — | — | — | |||||
| Net income | — | — | — | — | — | — | — | — | — | — | |||||
| Depreciation | — | — | — | — | — | — | — | — | — | — | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Earnings | — | — | — | — | — | — | — | — | — | — | |||||
| Cash flow | — | — | — | — | — | — | — | — | — | — | |||||
| Capex | — | — | — | — | — | — | — | — | — | — | |||||
| Free cash flow | — | — | — | — | — | — | — | — | — | — | |||||
| Book value | — | — | — | — | — | — | — | — | — | — | |||||
| Shares, m | — | — | — | — | — | — | — | — | — | — | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | — | — | ||||
| Capex | — | — | — | — | — | — | — | — | — | — | |||||
| Free cash flow | — | — | — | — | — | — | — | — | — | — | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | — | — | ||||
| Total debt | — | — | — | — | — | — | — | — | — | — | |||||
| Net debt | — | — | — | — | — | — | — | — | — | — | |||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | — | — | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | — | — | — | ||||
| ROIC | — | — | — | — | — | — | — | — | — | — | |||||
| ROE | — | — | — | — | — | — | — | — | — | — | |||||
Negative figures in brackets.
Charts ten years each
Drugs Made In America Acquisition Corp. vs peers in Shell Companies (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| AXIN Axiom Intelligence Acquisition Corp 1 | $282.5M | — | — | — | — | — | — | — | Compare |
| PAII Pyrophyte Acquisition Corp. II | $281.4M | — | — | — | — | — | — | — | Compare |
| SOUL Soulpower Acquisition Corporation | $274.9M | — | — | — | — | — | — | — | Compare |
| CEPO Cantor Equity Partners, Inc. | $274.4M | — (loss-making) | — | — | +225.00% (above 0%: growing) | 0.00% | — | 0.00% | Compare |
| DNMX Dynamix Corporation III | $271.0M | — | — | — | — | — | — | 0.00% | Compare |
| DMAA Drugs Made In America Acquisition Corp. | $263.8M | — | — | — | — | — | — | — | |
| OACC Oaktree Acquisition Corp. III Life Sciences | $261.8M | — | — | — | — | — | — | — | Compare |
| RAC Rithm Acquisition Corp. | $256.8M | — | — | — | — | — | — | — | Compare |
| SZZL Sizzle Acquisition Corp. II | $250.9M | — | — | — | — | — | — | — | Compare |
| Median of peers | $272.7M | — | — | — | — | — | — | — |